Immorta Bio Appoints Howard Brooks to its Corporate Board
Scientific longevity company Immorta Bio has appointed former Ernst & Young Health Sciences Partner Howard Brooks to its board, enhancing governance and strategic leadership as the firm advances toward clinical development. The addition of Mr. Brooks brings over three decades of experience in healthcare strategy and capital formation.
Topics: capital_markets governance leadership